135 related articles for article (PubMed ID: 37655708)
1. Baseline Peripheral Blood Mononuclear Cell Transcriptomics Before Ustekinumab Treatment Is Linked With Crohn's Disease Clinical Response at 1 Year.
Granot M; Braun T; Efroni G; Picard O; Fudim E; Yavzori M; Haj O; Weiss B; Ben-Horin S; Kopylov U; Haberman Y
Clin Transl Gastroenterol; 2023 Dec; 14(12):e00635. PubMed ID: 37655708
[TBL] [Abstract][Full Text] [Related]
2. Identifying hub genes in response to ustekinumab and the impact of ustekinumab treatment on fibrosis in Crohn's disease.
Xu Y; Wang S; Ye Z; Zhang H
Front Immunol; 2024; 15():1401733. PubMed ID: 38840917
[TBL] [Abstract][Full Text] [Related]
3. Ustekinumab in treatment of Crohn's disease: design, development, and potential place in therapy.
Deepak P; Loftus EV
Drug Des Devel Ther; 2016; 10():3685-3698. PubMed ID: 27956825
[TBL] [Abstract][Full Text] [Related]
4. Anti-IL-12/23p40 antibodies for maintenance of remission in Crohn's disease.
Davies SC; Nguyen TM; Parker CE; MacDonald JK; Jairath V; Khanna R
Cochrane Database Syst Rev; 2019 Dec; 12(12):CD012804. PubMed ID: 31828765
[TBL] [Abstract][Full Text] [Related]
5. Ustekinuma b for Crohn's Disease: Two-Year Results of the Initiative on Crohn and Colitis (ICC) Registry, a Nationwide Prospective Observational Cohort Study.
Straatmijer T; Biemans VBC; Hoentjen F; de Boer NKH; Bodelier AGL; Dijkstra G; van Dop WA; Haans JJL; Jansen JM; Maljaars PWJ; van der Marel S; Oldenburg B; Ponsioen CY; Visschedijk MC; de Vries AC; West RL; van der Woude CJ; Pierik M; Duijvestein M; van der Meulen-de Jong AE
J Crohns Colitis; 2021 Nov; 15(11):1920-1930. PubMed ID: 33909062
[TBL] [Abstract][Full Text] [Related]
6. Transcriptional regulation of chemokine network by biologic monotherapy in ileum of patients with Crohn's disease.
Linares R; Gutiérrez A; Márquez-Galera Á; Caparrós E; Aparicio JR; Madero L; Payá A; López-Atalaya JP; Francés R
Biomed Pharmacother; 2022 Mar; 147():112653. PubMed ID: 35078095
[TBL] [Abstract][Full Text] [Related]
7. Intestinal mRNA expression profiles associated with mucosal healing in ustekinumab-treated Crohn's disease patients: bioinformatics analysis and prospective cohort validation.
Li Q; Huang Z; Yang H; Tang J; Zuo T; Yang Q; Huang Z; Guo Q; Li M; Gao X; Chao K
J Transl Med; 2024 Jun; 22(1):595. PubMed ID: 38926732
[TBL] [Abstract][Full Text] [Related]
8. Endoscopic Activity and Serum TNF-α Level at Baseline Are Associated With Clinical Response to Ustekinumab in Crohn's Disease Patients.
Murate K; Maeda K; Nakamura M; Sugiyama D; Wada H; Yamamura T; Sawada T; Mizutani Y; Ishikawa T; Furukawa K; Ohno E; Honda T; Kawashima H; Miyahara R; Ishigami M; Nishikawa H; Fujishiro M
Inflamm Bowel Dis; 2020 Oct; 26(11):1669-1681. PubMed ID: 32405651
[TBL] [Abstract][Full Text] [Related]
9. Ustekinumab Inhibits T Follicular Helper Cell Differentiation in Patients With Crohn's Disease.
Globig AM; Sommer NP; Wild K; Schardey J; Zoldan K; Thomann AK; Schulte LA; Schreiner R; Reindl W; Klaus J; Schempp CM; Hofmann M; Thimme R; Boettler T; Hasselblatt P
Cell Mol Gastroenterol Hepatol; 2021; 11(1):1-12. PubMed ID: 32679193
[TBL] [Abstract][Full Text] [Related]
10. Anti-IL-12/23p40 antibodies for induction of remission in Crohn's disease.
MacDonald JK; Nguyen TM; Khanna R; Timmer A
Cochrane Database Syst Rev; 2016 Nov; 11(11):CD007572. PubMed ID: 27885650
[TBL] [Abstract][Full Text] [Related]
11. Higher Ustekinumab Levels in Maintenance Therapy are Associated with Greater Mucosal Healing and Mucosal Response in Crohn's Disease: An Experience of 2 IBD Centers.
McDonald C; Kerr H; Gibbons E; Lukose T; Cheriyan D; Harewood G; Patchett S; O'Toole A; Kelly O; Boland K
Inflamm Bowel Dis; 2024 Mar; 30(3):423-428. PubMed ID: 37158577
[TBL] [Abstract][Full Text] [Related]
12. Ustekinumab: "Real-world" outcomes and potential predictors of nonresponse in treatment-refractory Crohn's disease.
Hoffmann P; Krisam J; Wehling C; Kloeters-Plachky P; Leopold Y; Belling N; Gauss A
World J Gastroenterol; 2019 Aug; 25(31):4481-4492. PubMed ID: 31496626
[TBL] [Abstract][Full Text] [Related]
13. Anti-IL-12/23p40 antibodies for induction of remission in Crohn's disease.
Khanna R; Preiss JC; MacDonald JK; Timmer A
Cochrane Database Syst Rev; 2015 May; (5):CD007572. PubMed ID: 25942580
[TBL] [Abstract][Full Text] [Related]
14. Ustekinumab: a novel therapeutic option in Crohn's disease.
Simon EG; Samuel S; Ghosh S; Moran GW
Expert Opin Biol Ther; 2016 Aug; 16(8):1065-74. PubMed ID: 27341173
[TBL] [Abstract][Full Text] [Related]
15. Ustekinumab in Crohn's Disease: New Data for Positioning in Treatment Algorithm.
D'Amico F; Peyrin-Biroulet L; Danese S
J Crohns Colitis; 2022 May; 16(Supplement_2):ii30-ii41. PubMed ID: 35553665
[TBL] [Abstract][Full Text] [Related]
16. IL-12p40/IL-23p40 Blockade With Ustekinumab Decreases the Synovial Inflammatory Infiltrate Through Modulation of Multiple Signaling Pathways Including MAPK-ERK and Wnt.
Fiechter RH; de Jong HM; van Mens LJJ; Fluri IA; Tas SW; Baeten DLP; Yeremenko NG; van de Sande MGH
Front Immunol; 2021; 12():611656. PubMed ID: 33746955
[No Abstract] [Full Text] [Related]
17. Comparative Efficacy of Infliximab vs Ustekinumab for Maintenance of Clinical Response in Biologic Naïve Crohn's Disease.
Wong ECL; Dulai PS; Marshall JK; Jairath V; Reinisch W; Narula N
Inflamm Bowel Dis; 2023 Jul; 29(7):1015-1023. PubMed ID: 35920382
[TBL] [Abstract][Full Text] [Related]
18. A randomized trial of Ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with moderate-to-severe Crohn's disease.
Sandborn WJ; Feagan BG; Fedorak RN; Scherl E; Fleisher MR; Katz S; Johanns J; Blank M; Rutgeerts P;
Gastroenterology; 2008 Oct; 135(4):1130-41. PubMed ID: 18706417
[TBL] [Abstract][Full Text] [Related]
19. Matching-Adjusted Indirect Comparison Between Risankizumab and Ustekinumab for Induction and Maintenance Treatment of Moderately to Severely Active Crohn's Disease.
Dubinsky M; Ma C; Griffith J; Crowell M; Neimark E; Kligys K; O'Connell T
Adv Ther; 2023 Sep; 40(9):3896-3911. PubMed ID: 37368103
[TBL] [Abstract][Full Text] [Related]
20. Adalimumab versus ustekinumab as first-line biological in moderate-to-severe Crohn's disease: real-life cohort from a tertiary referral center.
Moens A; Alsoud D; Verstockt B; Sabino J; Ferrante M; Vermeire S
Eur J Gastroenterol Hepatol; 2022 Oct; 34(10):1015-1020. PubMed ID: 36062494
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
